Concepedia

Developing an efficient MGCR microneedle nanovaccine patch for eliciting Th 1 cellular response against the SARS-CoV-2 infection

Ang Gao, Yunsheng Chen, Hui Liang, Xinyuan Cui, Amin Zhang, Daxiang Cui

Theranostics · 2023 · 14 citations · 28 references

DOIFull text

Open access

Concepts

Abstract

The vaccine system could significantly improve the vaccine distribution rate in low-income areas and offer a potential vaccination approach to fight against the SARS-Cov-2 infection and other pandemics occurred in the future.

References

28

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Kizzmekia S. Corbett, Darin K. Edwards, Sarah R. Leist et al. · Nature · 2020 · 1.7K citations · Full text

, , +14

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial

Fengcai Zhu, Yu-Hua Li, Xu-Hua Guan et al. · The Lancet · 2020 · 1.5K citations · Full text

, , +17

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

The Lancet · 2020 · 1.4K citations · Full text

, , +17

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Cheryl Keech, Gary Albert, Iksung Cho et al. · New England Journal of Medicine · 2020 · 1.2K citations · Full text

, , +17

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial

Amy Ross-Russell, Nisha Singh · Oxford University Research Archive (ORA) (University of Oxford) · 2020 · 1.2K citations · Full text

, , +17